Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
Sponsored by TG Therapeutics, Inc.
About this trial
Last updated 3 years ago
Study ID
TG-1501-101
Status
Terminated
Type
Interventional
Phase
Phase 1
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 3 years ago
What is this trial about?
Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or
refractory B-cell Non Hodgkin's Lymphoma.
What are the Participation Requirements?
Key Inclusion Criteria:
- Histologically confirmed relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
- Measurable disease and adequate organ function as specified in the protocol
Key Exclusion Criteria:
- Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or prior therapy with
bendamustine.
- Subjects receiving cancer therapy or investigational drug within 21 days of Cycle 1
Day 1.
- Prior autologous stem cell transplant within 3 months
- Active Hepatitis B or Hepatitis C